Navigation Links
Georgia physicians' study published in the Journal of Urology
Date:2/27/2013

ATLANTA The March 2013 issue of The Journal of Urology, the official journal of The American Urological Association, includes a study conducted by four physicians from Radiotherapy Clinics of Georgia (RCOG), a Vantage Oncology affiliate. This study, 25 Year Disease Free Survival Rate after Irradiation of Prostate Cancer Calculated with the Prostate Specific Antigen Definition of Recurrence Used for Radical Prostatectomy, is the first-ever to analyze 25 years of follow-up data after radiation therapy treatment for prostate cancer patients.

Frank Critz, M.D., founder and medical director at RCOG, the largest community-based prostate program in the United States, co-wrote this study along with three other RCOG physicians, James Benton, M.D., Philip Shrake, M.D., and Mark Merlin, M.D. The prostate program at RCOG is the only program of its kind to have gathered and maintained a clinical records database for all patients over a 30-year period in a consistent and comprehensive manner.

"This study, the longest after irradiation of prostate cancer, confirms using the surgical PSA definition (PSA <0.2 ng/ml) that results from this program are equal to that of radical prostatectomy, thus giving men a choice of treatment and after 15 year follow up if the PSA is <0.2, late recurrence will be rare."

This research study included 3,546 hormone nave men with prostate cancer treated by I-125 implant followed by external beam radiation. The initial cohort was treated with retropubic implants, and as technology improved, the implant technique was changed to a transperineal template/ultrasound guided approach, which was the technique used in 2,875 of these men. Seventy three percent of men had no evidence of prostate cancer 25 years after this irradiation program. To compare like populations, this study compares patients treated between 1984-2000 to two previous prostatectomy studies which analyze 15 years of follow up data and a disease-free survival (DFS) calculation with a PSA<0.2. The surgical definition is much stricter than the one usually used in radiation therapy studies. Results showed comparable DFS at 10 (75 percent, 77 percent, 77 percent) and 15 years of follow up (73 percent, 68 percent, 75 percent). A sub analysis of patients treated with transperineal implants between 1995 and 2000 showed a 15 year disease-free survival (DFS) of 79 percent.

The analysis includes over 300 men whose prostate cancer recurred who were treated 16-25 years ago. Recurrences were PSA defined and results showed the majority of recurrences occurred within the first five years after treatment and no recurrences were noted15.5-25 years after treatment.

This study concludes that follow up evaluations are necessary for 15 years after treatment to fully understand the outcomes of any treatment for prostate cancer. Unlike a previous study on patients recurring after prostatectomy, this is the first to include interval censoring analysis when looking at time to recurrence. If a man's PSA is <0.20 ng/ml 15 years post treatment, later recurrence of the disease should be rare.


'/>"/>
Contact: Logan Moses
LMoses@golinharris.com
404-367-2743
Radiotherapy Clinics of Georgia
Source:Eurekalert

Related medicine news :

1. The MS Center of Atlanta Partners with Georgia Partnership for TeleHealth
2. Fourth Annual Georgia Partnership for Telehealth, Inc. Conference, Impacting Lives Through Applied Technology, to be held March 18-20th 2013 in Savannah, Georgia
3. Georgia Partnership for TeleHealth Presents to the FCC in Washington DC
4. Georgia State researcher gets $3.4 million grant to develop vaccine technology against flu, RSV
5. New target to stop cancers spread discovered by Georgia State scientists
6. ShapeMed - http://www.ShapeMed.com - Offers Testosterone Screening for Men in Georgia
7. Halcyon Completes First Acquisition in South Georgia
8. Childcare Network Announces Acquisition of 22 Learning Centers from Children’s Friend of Georgia
9. Metro Atlanta ServiceMasters Team Up to Offer Higher Quality of Water Damage, Mold Removal, Carpet Cleaning and Fire Damage Services to Customers in North Georgia
10. Way to make one-way flu vaccine discovered by Georgia State researcher
11. Piedmont Orthopaedic Complex is First to Provide Baseline Brain Function Test for Athletes in Central Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman ... Van Allen have signed a joint enrollment and degree completion agreement. The ... associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students to ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , ... Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated ... hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We ...
(Date:2/5/2016)... ... 05, 2016 , ... Regular gym users know the routine: each January, they ... access the treadmills. It’s a predictable trend. After the excesses of November and December, ... shape by joining gyms, starting new walking or running routines, or signing up for ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... in the 2015 Best in KLAS: Software & Services for HIT Implementation Support ... in KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians ...
(Date:2/5/2016)... WORCESTER, MA (PRWEB) , ... February 05, 2016 , ... ... latest in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal ... cutting-edge option with unmatched results. , Developed by Cynosure, the PicoSure has been approved ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
Breaking Medicine Technology: